Immutep (IMMP) Profit After Tax (2011 - 2024)
Immutep's (IMMP) quarterly Profit After Tax came in at -$2.6 million in Q4 2024, down 113.59% YoY from $19.4 million in Q1 2024, and up 90.62% on a QoQ basis from -$28.2 million in Q2 2024.
Immutep (IMMP) Profit After Tax (2011 - 2024) Analysis & Trends
Immutep (IMMP) has 14 years of Profit After Tax data on file, last reported at -$2.6 million in Q4 2024.
- Quarterly Profit After Tax fell 113.59% year-over-year to -$2.6 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$58.7 million (down 103.39% YoY) and the FY2025 annual result came in at -$39.3 million, down 39.76% from the prior year.
- Profit After Tax rose to -$2.6 million in Q4 2024, from -$28.2 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$422669.6 in Q4 2021 to a low of -$28.2 million in Q2 2024.
- A 5-year average of -$9.8 million and a median of -$2.6 million in 2024 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2020 — Profit After Tax soared 31.3% — and 2023, when it tumbled 131.58%.
- Tracing IMMP's Profit After Tax over 5 years: stood at -$8.8 million in 2020, then soared by 95.21% to -$422669.6 in 2021, then fell by 26.34% to -$534020.1 in 2022, then slumped by 131.58% to -$1.2 million in 2023, then slumped by 113.59% to -$2.6 million in 2024.
- The last three Profit After Tax figures came in at -$2.6 million (Q4 2024), -$28.2 million (Q2 2024), and -$1.2 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Immutep | 56.46 Mn | -8.63 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -2.64 Mn |
| Jun 30, 2024 | -28.15 Mn |
| Dec 31, 2023 | -1.24 Mn |
| Jun 30, 2023 | -26.67 Mn |
| Dec 31, 2022 | -534,020.09 |
| Dec 31, 2021 | -422,669.57 |
| Jun 30, 2020 | -8.83 Mn |
| Dec 31, 2019 | -670,750.76 |
| Jun 30, 2019 | -12.85 Mn |
| Dec 31, 2018 | -944,731.60 |
| Jun 30, 2017 | -7.04 Mn |
| Mar 31, 2017 | -1.80 Mn |
| Dec 31, 2016 | -461,772.75 |
| Jun 30, 2016 | -46.31 Mn |
| Mar 31, 2016 | -1.99 Mn |
| Jun 30, 2015 | -25.00 Mn |
| Jun 30, 2014 | -12.44 Mn |
| Jun 30, 2013 | -15.13 Mn |
| Dec 31, 2012 | 69,562.20 |
| Jun 30, 2012 | -20.15 Mn |